Highlights Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:53:07 10/02/2026 GMT			5-day change	1st Jan Change
15.46 ^USD	+3.24%		+5.76%	-11.78%

01-29	Sector Update: Health Care Stocks Edge Higher Premarket Thursday	MT
01-29	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI

Highlights

01-29	Sector Update: Health Care Stocks Edge Higher Premarket Thursday	MT
01-29	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI
01-12	Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC	CI
01-12	Summit Therapeutics, GSK Team up on Clinical Trial for Combination Cancer Therapy	MT
01-12	Summit Therapeutics Files Marketing Application for Lung Cancer Therapy	MT
01-12	Summit Therapeutics Announces Clinical Trial Collaboration with GSK plc to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate	CI
12-09	Akeso, Inc. Announces Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia	CI
11-07	Akeso Announces Final OS Analysis Results Of Ivonescimab HARMONi-A Study At SITC 2025	CI
24/10/25	Summit Therapeutics Insider Bought Shares Worth $9,999,983, According to a Recent SEC Filing	MT
21/10/25	The Calm Before the Quarterly Storm
20/10/25	Summit Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
20/10/25	Stocks Rise Pre-Bell as Traders Await Earnings, Key Inflation Data; AWS-Linked Internet Outage Impacts Major Websites	MT
20/10/25	Summit Therapeutics Q3 Non-GAAP Net Loss Widens, Shares Decline Pre-Bell	MT
20/10/25	Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q3 Adjusted Loss $0.13 per Share	MT
20/10/25	Summit Therapeutics Inc. Plans to Submit a BLA in Fourth Quarter 2025 for Ivonescimab Based on Harmoni Global Phase III Study Results	CI
19/10/25	Summit Intends to Open Clinical Trial Sites in the United States for the Phase Iii Harmoni-Gi3 Study in Colorectal Cancer by the End of 2025	CI
17/10/25	Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with Harmoni-GI3 Study in 1L Colorectal Cancer	CI
15/10/25	Summit Therapeutics to host Esmo data update & third quarter earnings call on October 20, 2025	RE
24/09/25	Summit Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4)	RE
24/09/25	Summit Therapeutics Inc. Announces Data from the Phase III HARMONi-6 Trial	CI
08/09/25	Top Midday Decliners	MT
07/09/25	Summit Therapeutics Inc. Announces Data from the Phase III HARMONi Trial Featuring the Novel, Potential First-In-Class Investigational Bispecific Antibody, Ivonescimab	CI
03/09/25	Summit Therapeutics Inc. to Discuss Full Presentation Data from HARMONi, the Global Phase III Clinical Trial Featured in the Presidential Symposium at WCLC 2025	CI
14/08/25	Summit Therapeutics Inc. Announces Data from the Phase III Harmoni Trial Featuring the Novel, Potential First-In-Class Investigational Bispecific Antibody, Ivonescimab	CI
11/08/25	Summit Therapeutics Q2 Adjusted Loss Widens	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Biotechnology & Medical Research

Highlights

Filters